Compare SABS & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | OSUR |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 174.3M |
| IPO Year | N/A | 1986 |
| Metric | SABS | OSUR |
|---|---|---|
| Price | $4.45 | $2.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $9.80 | $3.00 |
| AVG Volume (30 Days) | 414.6K | ★ 582.5K |
| Earning Date | 11-13-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $114,698.00 | ★ $125,703,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $2.08 |
| 52 Week High | $6.60 | $4.22 |
| Indicator | SABS | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 72.95 | 55.11 |
| Support Level | $3.93 | $2.64 |
| Resistance Level | $4.21 | $2.79 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 83.87 | 62.50 |
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.